Researchers discover mechanism in cells that leads to inflammatory diseases

Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.

The study, funded by the National Institutes of Health, is published online by the peer-reviewed journal Immunity and will appear in the March print edition.

The researchers identified for the first time the mechanism that leads to the production of the molecule interleukin-1beta. It is a major contributor to inflammation, which lies at the root of many serious health conditions, including atherosclerotic heart disease and some types of strokes.

Current drug therapies seek to block this molecule's action after it is secreted by cells. However, the new research could lead to the development of treatments that would prevent the body from producing it, resulting in more effective medications and therapies for .

"If we understand how this molecule is made in the body, we may be able to block it before it is produced," said study author Dr. Moshe Arditi, executive vice chair of research in the Department of Pediatrics and director of the Division of Pediatric and Immunology. "Until now, this was the missing piece of the puzzle."

Arditi, who also directs Cedars-Sinai's Infectious and Immunologic Diseases Research Center, found that damaged activate specific proteins within , triggering the release of interleukin-1beta. Previous research has shown the molecule, when over-secreted by cells, can be a significant contributor to major inflammatory diseases.

Three of these diseases alone -- atherosclerosis, and – affect an estimated 100 million Americans.

Arditi is planning further studies to build on the findings.

"The discovery by Arditi and colleagues has great potential to impact a wide range of inflammatory diseases, particularly in their early stages where an intervention could prevent more severe and debilitating ravages of such diseases," said Dr. Leon Fine, Cedars-Sinai's vice dean of research and chair of biomedical sciences. "This discovery, at last, may open the door to such therapy."

In addition to Cedars-Sinai, other research groups involved in the study include UCLA 's David Geffen School of Medicine, UC Merced's Health Sciences Research Institute and School of Natural Sciences; UC Riverside's Department of Chemistry and the University of Massachusetts Medical School's Department of Medicine.

Provided by Cedars-Sinai Medical Center

5 /5 (1 vote)

Related Stories

New drug target for immune diseases discovered

Aug 03, 2010

Researchers from Mount Sinai School of Medicine have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present ...

Recommended for you

Taking the sting out of insect-sting allergies

Apr 11, 2014

(Medical Xpress)—Certain people with a history of systemic allergic reactions to insect stings are likely to benefit from immunotherapy to prevent life-threatening anaphylaxis and should, at the very least, ...

Sensitive balance in the immune system

Apr 11, 2014

Apoptosis is used by cells that are changed by disease or are simply not needed any longer to eliminate themselves before they become a hazard to the body—on a cellular level, death is part of life. Disruption ...

Researchers find that influenza has an Achilles' heel

Apr 10, 2014

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study published by Cell Press on April 10 in the journal ...

User comments